Amphastar Pharmaceuticals Files 8-K
Ticker: AMPH · Form: 8-K · Filed: May 7, 2025 · CIK: 1297184
| Field | Detail |
|---|---|
| Company | Amphastar Pharmaceuticals, Inc. (AMPH) |
| Form Type | 8-K |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, sec-filing
Related Tickers: AMPH
TL;DR
AMPH filed an 8-K on May 7th, likely covering financial results.
AI Summary
On May 7, 2025, Amphastar Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Amphastar Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — This is a routine SEC filing reporting financial information and exhibits, with no immediate indication of significant new risks.
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Registrant
- May 7, 2025 (date) — Report Date
- 0001297184-25-000025 (filing_id) — Accession Number
FAQ
What is the primary purpose of this 8-K filing by Amphastar Pharmaceuticals?
The filing is intended to report on Amphastar Pharmaceuticals, Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on May 7, 2025.
What is Amphastar Pharmaceuticals' principal executive office address?
The principal executive offices are located at 11570 6th Street, Rancho Cucamonga, California 91730.
What is Amphastar Pharmaceuticals' phone number?
The registrant's telephone number, including area code, is (909) 980-9484.
Under which section of the Securities Exchange Act is this report filed?
This is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 7, 2025 regarding Amphastar Pharmaceuticals, Inc. (AMPH).